Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities

The prognostic and therapeutic relevance of molecular subtypes for the most aggressive isocitrate dehydrogenase 1/2 (IDH) wild-type glioblastoma (GBM) is currently limited due to high molecular heterogeneity of the tumors that impedes patient stratification. Here, we describe a distinct binary class...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Sejin, Yeom, Jeonghun, Cho, Hee Jin, Kim, Ju-Hwa, Yoon, Seon-Jin, Kim, Hakhyun, Sa, Jason K., Ju, Shinyeong, Lee, Hwanho, Oh, Myung Joon, Lee, Wonyeop, Kwon, Yumi, Li, Honglan, Choi, Seunghyuk, Han, Jang Hee, Chang, Jong Hee, Choi, Eunsuk, Kim, Jayeon, Her, Nam-Gu, Kim, Se Hoon, Kang, Seok-Gu, Paek, Eunok, Nam, Do-Hyun, Lee, Cheolju, Kim, Hyun Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335111/
https://www.ncbi.nlm.nih.gov/pubmed/32620753
http://dx.doi.org/10.1038/s41467-020-17139-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335111/
https://www.ncbi.nlm.nih.gov/pubmed/32620753
http://dx.doi.org/10.1038/s41467-020-17139-y

Ejemplares similares